Drug Database
LI

Livact Jelly (Livact Jelly)

✓ Approved

Ajinomoto · therapeutic agent

What is Livact Jelly?

Livact Jelly is a therapeutic agent developed by Ajinomoto. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesLivact Jelly
CompanyAjinomoto
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Ajinomoto

Therapeutic Indications

Livact Jelly is developed for 2 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Hepatobiliary disordersHepatic cirrhosis✓ Approved
Metabolism and nutrition disordersHypoalbuminaemia✓ Approved

Related Research Articles

PubMedFood chemistry2026-10-18

Current trends in the analysis of mycotoxins in bee products: Occurrence, extraction, and determination.

Brugnerotto Patricia P, Fuente-Ballesteros Adrián A, Antunes Ana Clara Nascimento ACN, Ares Ana M AM et al.

Bee products, including honey, bee pollen, propolis, and royal jelly, are increasingly valued for their nutritional and bioactive properties. However, these matrices may also be contaminated by mycotoxins, toxic secondary metabolites produced by fungi under inadequate agricultural and storage conditions. Although mycotoxin contamination has been extensively investigated in cereals and animal feed, studies involving bee products remain limited, despite their increasing consumption and commercial relevance. This review is the first to comprehensively compile and critically discuss current methodologies for the extraction and determination of mycotoxins specifically in bee products. Emphasis is placed on advances reported over approximately the last five years, including improvements in sample preparation and the application of chromatographic and mass spectrometric techniques. Additionally, occurrence data are examined in light of analytical performance, limitations, and emerging challenges. The implementation of sensitive and robust analytical strategies is essential to ensure product safety, support regulatory monitoring, and preserve the functional quality of bee-derived foods within the global food system.

PMID 42892026
Read full article →
PubMedIranian journal of basic medical sciences2026-10-17

Enhanced effects of Wharton's jelly-derived MSC secretome and microbial exopolysaccharide on cellular responses and tissue repair in diabetic wound healing.

Rostami Hossein H, Haramshahi Seyed Mohamad Amin SMA, Vousooghi Nasim N, Shamlou Somayeh S et al.

Diabetic wounds are characterized by impaired healing and chronic inflammation. This study evaluated a combination therapy using an exopolysaccharide derived from Rhodotorula mucilaginosa sp. GUMS16 (EPS-GUMS16) and Wharton's jelly-derived mesenchymal stem cell-conditioned medium (WCM) to accelerate wound repair. Human foreskin fibroblasts (HFFs) and human umbilical vein endothelial cells (HUVECs) were treated with an optimized concentration of the WCM/EPS-GUMS16 (WCM/EPS) combination. In vitro assays, including MTT and scratch wound assays, were conducted to assess cell proliferation and migration. In vivo, full-thickness wounds in diabetic rats were treated with WCM/EPS via subcutaneous injection and topical application. Wound healing was monitored by measuring the reduction in wound surface area, and histopathological evaluation was performed using hematoxylin and eosin (H&E) and Masson's trichrome (MT) staining. In vitro assessments showed that WCM/EPS enhanced fibroblast proliferation and migration (P<0.05) and significantly upregulated CDK-4 expression (P<0.05). In vivo, treated wounds exhibited increased epidermal thickness and altered blood vessel density compared with controls. Semi-quantitative histopathological analysis further revealed enhanced re-epithelialization, more organized granulation tissue, and reduced inflammation and edema. These findings indicate that WCM/EPS effectively modulates inflammation and angiogenesis, thereby promoting tissue regeneration in diabetic wounds. Overall, this combination is a promising strategy for improving diabetic wound healing and highlights the potential of integrating microbial exopolysaccharides with stem cell-derived conditioned media in regenerative therapies.

PMID 42889629
Read full article →
PubMedInternational journal of molecular sciences2026-10-16

BMP-7 Enhances the Angiogenic Potential of Wharton's Jelly Mesenchymal Stem Cells Seeded in Decellularized Human Dental Pulp.

Peh Wei Ying WY, Abdullah Dalia D, Ng Sook Luan SL, Soo Eason E et al.

Regeneration of a pulp-dentin complex requires coordinated angiogenesis. This study investigated the angiogenic potential of Wharton's jelly mesenchymal stem cells (WJMSCs) in decellularized human dental pulp (DHDP) treated with bone morphogenetic protein-7 (BMP-7). Decellularized human dental pulp tissues were repopulated with WJMSCs, with or without BMP-7 (50 ng/mL). Degradation rate, swelling ratio, and pore size of DHDP samples were assessed. DHDP and repopulated DHDP were evaluated through hematoxylin and eosin and 4', 6-diamidino-2-phenylindole staining, and field-emission scanning electron microscopy. Biocompatibility of DHDP, BMP-7, and DHDP+BMP-7 on WJMSCs was assessed using the MTT assay. WJMSCs' viability was evaluated using a resazurin-based assay on days 7, 14, and 21. Angiogenic potential was assessed by measuring vascular endothelial growth factor-A (VEGFA) gene expression via quantitative reverse transcriptase polymerase chain reaction and VEGF-A protein expression via immunohistochemistry. At 21 days, DHDP exhibited a degradation rate of 40.19%, moderate swelling (77.22 ± 0.59%), and a significantly larger mean pore size (12.393 ± 0.638 µm2) than HDP (5.956 ± 0.501 µm2; p = 0.039). Histologically, DHDP exhibited complete nuclei removal, while WJMSCs were well integrated into the DHDP stroma. DHDP, BMP-7, and DHDP+BMP-7 were non-cytotoxic to WJMSCs. The DHDP+WJMSC+BMP-7 group demonstrated significantly higher cell viability at all time points compared with DHDP+WJMSC alone (p < 0.01), and VEGFA expression was significantly increased at both mRNA (p = 0.002) and protein levels. BMP-7 (50 ng/mL) can enhance WJMSC proliferation and VEGFA/VEGF-A expression within DHDP scaffolds while maintaining biocompatibility.

PMID 42883846
Read full article →
PubMedAnimals : an open access journal from MDPI2026-10-16

A Retrospective Study on Mucous Stool Excretion in Giant Pandas: Statistical Analysis Based on CCRCGP Data.

Wang Pingfeng P, Zheng Xiaomei X, Feng Minfu M, Li Denghe D et al.

This retrospective multicenter study integrated individual- and event-level records from 190 captive giant pandas managed at four study sites of the China Conservation and Research Center for the Giant Panda (CCRCGP) during 2024 to characterize patterns of mucous stool excretion and associated phenotypic variation. Logistic and negative binomial regression models were used to evaluate individual-level associations with event occurrence and annual event frequency, while generalized estimating equations (GEEs) were applied to monthly and event-level analyses to account for repeated observations within pandas. Overall, 132 of 190 pandas (69.5%, 95% CI, 62.6-75.6%) experienced at least one mucous stool event, with 674 events recorded during the study year. Monthly event frequency differed significantly overall (Poisson GEE, p = 0.0015), with the largest observed event count occurring in July, although no individual month-versus-January comparison remained significant after Holm correction. The monthly probability of an individual panda experiencing at least one event did not differ significantly (p = 0.295). Mucous stool weight showed no significant monthly variation (p = 0.453) but differed markedly by physical phenotype, compared with jelly-like stools, lard-like and mixed jelly/lard stools were 1.318- and 2.133-fold heavier, respectively. An exploratory inverse association between body weight and event occurrence persisted after adjustment for age and sex (adjusted OR per kg = 0.961, 95% CI, 0.930-0.992, p = 0.015). Recurrently affected individuals contributed disproportionately to the annual event burden, but did not exclusively account for the elevated July count. These findings indicate that within-year variation primarily reflected changes in event burden rather than the proportion of affected pandas, while visible phenotype was strongly associated with the amount of mucous material excreted. The disproportionate contribution of recurrently affected individuals highlights the value of targeted longitudinal monitoring in veterinary and husbandry management, while multi-year prospective surveillance is needed to confirm reproducible temporal patterns and clarify underlying mechanisms.

PMID 42883016
Read full article →
PubMedMolecules (Basel, Switzerland)2026-10-16

Bee-Derived Products in Neurodegenerative Diseases: Bioactive Constituents, Redox-Modulating Mechanisms, Evidence, and Translational Perspectives.

Garbarek Jakub J, Hys Oskar O, Woźniak Alina A, Szewczyk-Golec Karolina K et al.

Oxidative stress, mitochondrial dysfunction, and chronic neuroinflammation are closely interconnected processes involved in the pathogenesis and progression of neurodegenerative diseases. Bee-derived products, including honey, propolis, royal jelly, bee pollen, bee bread, and bee venom, contain diverse bioactive constituents with antioxidant, anti-inflammatory, immunomodulatory, and redox-modulating properties. This narrative review summarizes the major bioactive compounds present in bee-derived products and evaluates their potential relevance to neuroprotection. Particular attention is given to mechanisms involving activation of the Nrf2/ARE antioxidant response, inhibition of NF-κB-dependent inflammatory signaling, modulation of the NLRP3 inflammasome, mitochondrial protection, regulation of apoptosis, and maintenance of proteostasis. Available evidence from cellular and animal models, together with the limited clinical data, is discussed primarily in the context of Alzheimer's and Parkinson's diseases, with additional consideration of amyotrophic lateral sclerosis and other neurodegenerative or neuroinflammatory conditions. Although several bee-derived products and isolated constituents show promising biological effects, their therapeutic translation remains limited by variable chemical composition, insufficient standardization, low or uncertain bioavailability, limited evidence of central nervous system exposure, and safety concerns. Further mechanistic, pharmacokinetic, and well-controlled clinical studies are therefore required before their potential neuroprotective applications can be reliably established.

PMID 42883328
Read full article →
PubMedInternational journal of molecular sciences2026-10-16

Cord-Derived Stem Cells for Pediatric Autism Spectrum Disorder: Biological Rationale and Source-Specific Trial Design.

Hong Chang-Eui CE, Lyu Su-Yun SY

Autism spectrum disorder (ASD) affects approximately 1 in 31 children, yet no pharmacological agent targets its core symptoms, leaving a substantial therapeutic gap. Umbilical cord-derived mesenchymal stem/stromal cells (UC-MSCs) have emerged as a biologically rational candidate, because their immunomodulatory, anti-inflammatory, and neurotrophic properties align with the chronic neuroinflammation, peripheral immune dysregulation, and microglial overactivation that characterize ASD pathophysiology. This review synthesizes the mechanistic rationale, tissue-source biology, manufacturing and characterization standards, preclinical evidence, and clinical trial landscape for cord-derived cell therapy in pediatric ASD, and examines administration routes, post-treatment monitoring, and long-term safety. Across five published clinical trials employing cord blood mononuclear cells, autologous and allogeneic umbilical cord blood, UC-MSCs, bone marrow-derived MSCs, and Wharton's jelly-derived MSCs, short-term safety is the most consistent finding, whereas efficacy remains unresolved owing to small sample sizes, single-arm designs, and heterogeneous outcome measures; a completed randomized Phase II trial of a cord tissue MSC product, reported to date only in the trial registry, did not meet its primary endpoint. The central argument advanced here is that the proposed active component of cord-derived therapy is the purified MSC population rather than the heterogeneous mononuclear cell fraction; this proposition is supported by the CD14+ monocyte mechanism and by the one pediatric trial in which purified UC-MSC was added to a mononuclear preparation, but it has not been confirmed in any clinical study and remains a hypothesis. Advancing the field requires dedicated source-specific randomized controlled trials integrating product standardization, patient stratification, and dose-route-timing optimization.

PMID 42883881
Read full article →

+7526 more articles available with a free account

Sign up free to view all articles →

Ask about Livact Jelly